Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 77
  1. Jan 08, 2026 · 07:34 · EPRX

    Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

    Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

    01
  2. Jan 08, 2026 · 06:30 · NGEN

    NervGen Pharma Begins Trading on Nasdaq Today

    NervGen Pharma Begins Trading on Nasdaq Today

    02
  3. Jan 08, 2026 · 04:48 · CNVI

    Conavi files amended final prospectus

    Conavi files amended final prospectus

    03
  4. Jan 08, 2026 · 04:40 · DRUG

    Bright Minds prices shares of offering at $90 each

    Bright Minds prices shares of offering at $90 each

    04
  5. Jan 08, 2026 · 04:00 · RKV

    Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

    Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

    05
  6. Jan 08, 2026 · 02:48 · 4565

    Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

    Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

    06
  7. Jan 07, 2026 · 21:38 · CNVI

    Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus

    Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus

    07
  8. Jan 07, 2026 · 21:33 · DRUG

    Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

    Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

    08
  9. Jan 07, 2026 · 18:01 · MYTC

    MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement

    MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement

    09
  10. Jan 07, 2026 · 17:56 · VPT

    Ventripoint increases financing to $1-million

    Ventripoint increases financing to $1-million

    10
  11. Jan 07, 2026 · 16:43 · MBX

    Microbix commercializes COVID-19 recombinant antigen

    Microbix commercializes COVID-19 recombinant antigen

    11
  12. Jan 07, 2026 · 08:51 · VPT

    Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

    Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

    12
  13. Jan 07, 2026 · 07:00 · MBX

    Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing

    Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing

    13
  14. Jan 06, 2026 · 20:18 · VIVI

    Tempramed receives first order in Israel

    Tempramed receives first order in Israel

    14
← Newer Older →